HIV and bone loss

被引：21

作者：

Arora S. ^{[1
,2
,3
]}

Agrawal M. ^{[1
]}

Sun L. ^{[1
]}

Duffoo F. ^{[1
,2
,3
]}

Zaidi M. ^{[1
]}

Iqbal J. ^{[1
]}

机构：

[1] Department of Medicine, Mount Sinai Bone Program, Mount Sinai School of Medicine, New York, NY 10029, One Gustave Levy Place

[2] Department of Internal Medicine, Wyckoff Heights Medical Center, New York, NY

[3] Weill Cornell Medical College, New York, NY

来源：

Current Osteoporosis Reports | 2010年 / 8卷 / 4期

关键词：

AIDS; BMD; Bone loss; HIV; Non-nucleoside reverse transcriptase inhibitors (NNRTIs); Nucleoside reverse transcriptase inhibitors (NRTIs); Protease inhibitors;

D O I：

10.1007/s11914-010-0036-x

中图分类号：

学科分类号：

摘要：

The use of antiretroviral therapy has significantly reduced the number of deaths due to HIV/AIDS. However, no current therapy can suppress the virus completely, and as the HIV-infected population continues to live longer new complications are emerging from the persistence of the virus and use of antiretroviral therapy. This review summarizes the clinical evidence linking HIV-associated osteoporosis to direct infection and antiretroviral therapy (ART) use. The purported molecular mechanisms involved in bone loss are also reviewed. Additionally, recommendations regarding the pharmacologic management of HIV/ART-related osteoporosis are given. © 2010 Springer Science+Business Media, LLC.

引用

页码：219 / 226

页数：7

共 51 条

[1]

AIDS Epidemic Update Regional Summary

[2]

Cazanave C., Dupon M., Lavignolle-Aurillac V., Et al., Reduced bone mineral density in HIV-infected patients: Prevalence and associated factors, AIDS, 22, pp. 395-402, (2008)

[3]

Arnsten J.H., Freeman R., Howard A.A., Et al., Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection, AIDS, 21, pp. 617-623, (2007)

[4]

Dolan S.E., Kanter J.R., Grinspoon S., Longitudinal analysis of bone density in human immunodeficiency virus-infected women, Journal of Clinical Endocrinology and Metabolism, 91, 8, pp. 2938-2945, (2006)

[5]

Brown T.T., Ruppe M.D., Kassner R., Kumar P., Kehoe T., Dobs A.S., Timpone J., Reduced bone mineral density in human immunodeficiency virus-infected patients and its association with increased central adiposity and postload hyperglycemia, Journal of Clinical Endocrinology and Metabolism, 89, 3, pp. 1200-1206, (2004)

[6]

Brown T.T., Qaqish R.B., Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: A meta-analytic review, AIDS, 20, 17, pp. 2165-2174, (2006)

[7]

Martin J.L., Brown C.E., Matthews-Davis N., Reardon J.E., Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis, Antimicrob Agents Chemother, 38, pp. 2743-2749, (1994)

[8]

Lewis W., Dalakas M.C., Mitochondrial toxicity of antiviral drugs, Nat Med, 1, pp. 417-422, (1995)

[9]

Moyle G.J., Datta D., Mandalia S., Morlese J., Asboe D., Gazzard B.G., Hyperlactataemia and lactic acidosis during antiretroviral therapy: Relevance, reproducibility and possible risk factors, AIDS, 16, 10, pp. 1341-1349, (2002)

[10]

Carr A., Miller J., Eisman J.A., Cooper D.A., Osteopenia in HIV-infected men: Association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy, AIDS, 15, 6, pp. 703-709, (2001)

← 1 2 3 4 5 6 →